Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 13/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29831705 | 1.00 | MRGPRX4 (0.51) | MRGPRX4TP53HTTFOLH1ALDH1A1 | |
| SCHEMBL24677760 | 0.88 | MRGPRX4 (0.46) | MRGPRX4HTTALDH1A1 | |
| SCHEMBL30447357 | 0.88 | MRGPRX4 (0.46) | MRGPRX4HTTALDH1A1 | |
| SCHEMBL30558899 | 0.88 | HTT (0.50) | MRGPRX4TP53HTTFOLH1ALDH1A1 | |
| SCHEMBL24677801 | 0.88 | HTT (0.50) | MRGPRX4TP53HTTFOLH1ALDH1A1 | |
| SCHEMBL17616627 | 0.82 | MRGPRX4 (0.62) | MRGPRX4TP53HTTFOLH1ALDH1A1 | |
| SCHEMBL25340996 | 0.79 | MRGPRX4 (0.71) | MRGPRX4 | |
| SCHEMBL24677759 | 0.77 | MRGPRX4 (0.47) | MRGPRX4HTTALDH1A1 | |
| SCHEMBL26507019 | 0.77 | RPS6KA1 (0.42) | MRGPRX4ALDH1A1 | |
| SCHEMBL24677758 | 0.76 | MRGPRX4 (0.46) | MRGPRX4TP53HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-20220306681-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, MC2R, NR3C2 | MRGPRX4 28/4885TP53 2988/4885HTT 4334/4885 |
| US-20220306681-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, MC2R, NR3C2 | MRGPRX4 28/4885TP53 2988/4885HTT 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.